Abstract Background Immunotherapy is a valuable option for cancer treatment, and the curative effect of anti-PD-1/PD-L1 therapy correlates closely with PD-L1 expression levels. Positron emission tomography (PET) imaging of PD-L1 expression is feasible using 68Ga-NOTA-Nb109 nanobody. 68Ga-NOTA-Nb109 was generated by radionuclide (68Ga) labeling of Nb109 using a NOTA chelator. To facilitate clinical trials, we explored the optimal dose range of 68Ga-NOTA-Nb109 in BALB/c A375-hPD-L1 tumor-burdened nude mice and C57-hPD-L1 transgenic MC38-hPD-L1 tumor-burdened mice by administration of a single intravenous dose of 68Ga-NOTA-Nb109 and confirmed the dose in cynomolgus monkeys. The biodistribution data of cynomolgus monkey PET images were extrapol...
The level of expression of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) is a pre...
PURPOSE: Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunoth...
F-18-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was develope...
Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) and its ligand PD-L1 have ...
Immune checkpoints, such as programmed death-ligand 1 (PD-L1), limit T-cell function and tumor cells...
Blockade of the inhibitory PD-1/PD-L1 immune checkpoint axis is a promising cancer treatment. Noneth...
Background Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodie...
Background Combination therapies that aim to improve the clinical efficacy to immune checkpoint inhi...
Recently, inhibiting the PD-1/PD-L1 checkpoint pathway utilizing anti-PD-1 or anti-PD-L1 antibodies ...
The programmed death-1 (PD-1) receptor is an immunosuppressive receptor expressed on activated T-cel...
There is no established method to assess the PD-L1 expression in brain tumours. Therefore, we invest...
One of the challenges that physicians face is the uncertainty that their therapy of choice will be e...
Objectives: Immune checkpoint blockade has emerged as a promising cancer treatment paradigm. Unfortu...
Abstract64Cu-DOTA-AE105 is a novel positron emission tomography (PET) tracer specific to the human u...
Purpose/Background:Immunotherapy, such as immune checkpoint blockade therapy (ICB), has revolutioniz...
The level of expression of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) is a pre...
PURPOSE: Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunoth...
F-18-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was develope...
Immune checkpoint inhibitors targeting the programmed cell death-1 (PD-1) and its ligand PD-L1 have ...
Immune checkpoints, such as programmed death-ligand 1 (PD-L1), limit T-cell function and tumor cells...
Blockade of the inhibitory PD-1/PD-L1 immune checkpoint axis is a promising cancer treatment. Noneth...
Background Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodie...
Background Combination therapies that aim to improve the clinical efficacy to immune checkpoint inhi...
Recently, inhibiting the PD-1/PD-L1 checkpoint pathway utilizing anti-PD-1 or anti-PD-L1 antibodies ...
The programmed death-1 (PD-1) receptor is an immunosuppressive receptor expressed on activated T-cel...
There is no established method to assess the PD-L1 expression in brain tumours. Therefore, we invest...
One of the challenges that physicians face is the uncertainty that their therapy of choice will be e...
Objectives: Immune checkpoint blockade has emerged as a promising cancer treatment paradigm. Unfortu...
Abstract64Cu-DOTA-AE105 is a novel positron emission tomography (PET) tracer specific to the human u...
Purpose/Background:Immunotherapy, such as immune checkpoint blockade therapy (ICB), has revolutioniz...
The level of expression of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) is a pre...
PURPOSE: Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunoth...
F-18-BMS-986192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was develope...